Focal Onset Seizure: Clinical Trials

2 completed, 2 recruiting, 1 active not recruiting, 1 terminated. 4 Phase 2, 1 Phase 4.

By phase and status

Phase	Trials	Status
Phase 2	4	Recruiting 2, Completed 1, Terminated 1
Phase 4	1	Active not recruiting 1

Follow Focal Onset Seizure: new trials by email Literature Review of Focal Onset Seizure trials Research Report on Focal Onset Seizure

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures RAP-219 - Focal Epilepsy, Epilepsy	Phase 2	Recruiting	Rapport Therapeutics Inc.	30	2025-12-15	2026-01-23
An Open Label Trial to Evaluate the Efficacy and Safety of PRAX-628 in Adults With Focal Onset or Tonic-Clonic Seizures 30mg PRAX-628 - Focal Onset Seizure, Primary Generalized Epilepsy	Phase 2	Recruiting	Praxis Precision Medicines	50	2025-01-10	2025-04-03
Open-label Study of Cenobamate Monotherapy in Adult Subjects With Newly Diagnosed or Recurrent Partial-Onset Epilepsy Cenobamate - Focal Onset Seizure	Phase 4	Active not recruiting	SK Life Science, Inc.	49	2024-10-14	2026-10-27
This is a Retrospective Study on the Use of CENOBAMATE as Adjunctive Treatment in Patients Suffering From Epilepsy in Early Access Program in Germany, France and UK Focal Onset Seizure, Epilepsy		Completed	Aziende Chimiche Riunite Angelini Francesco S.p.A	319	2023-01-27	2024-02-09
Extension Study to Evaluate the Safety and Tolerability of NBI-921352 When Used With Anti-seizure Medications in Adults With Focal Onset Seizures NBI-921352 - Focal Onset Seizure, Focal Onset Epilepsy	Phase 2	Terminated	Neurocrine Biosciences	82	2022-11-09	2024-04-12
A Study to Investigate How Effective, Safe and Tolerable the Drug NBI-921352 is When Used With Anti-seizure Medications in Adults With Focal Onset Seizures NBI-921352, Placebo - Focal Onset Seizure, Focal Onset Epilepsy	Phase 2	Completed	Neurocrine Biosciences	101	2021-11-08	2024-09-26

Narrower conditions

Seizures (6)  ·  Epilepsy (4)  ·  Epilepsies, Partial (1)  ·  Epilepsy, Idiopathic Generalized (1)

Broader conditions

Nervous System Diseases (6)  ·  Neurologic Manifestations (6)  ·  Pathological Conditions, Signs and Symptoms (6)  ·  Signs and Symptoms (6)  ·  Brain Diseases (4)  ·  Central Nervous System Diseases (4)

Interventions

Cenobamate (1)

Sponsors

Neurocrine Biosciences (2)  ·  Aziende Chimiche Riunite Angelini Francesco S.p.A (1)  ·  Praxis Precision Medicines (1)  ·  Rapport Therapeutics Inc. (1)  ·  SK Life Science, Inc. (1)

Countries

Australia (3)  ·  France (3)  ·  Spain (3)  ·  United States (3)  ·  Belgium (2)  ·  Czechia (2)  ·  Hungary (2)  ·  Italy (2)  ·  Germany (1)  ·  United Kingdom (1)

Top investigators

Felix Rosenow (1)  ·  Imran Quraishi, MD (1)  ·  Rhys Thoma (1)  ·  Sylvain Rheims (1)